MannKind Corp.

MannKind Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutic products for patients with serious medical conditions. Its primary product is Afrezza, a rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes mellitus. This novel approach provides an alternative to traditional insulin delivery methods, offering convenience and potentially improved patient compliance. MannKind Corporation operates in the health care sector, specifically targeting the pharmaceuticals and biotechnology industries. The company is dedicated to addressing unmet medical needs through its proprietary Technosphere formulation technology, which facilitates the pulmonary delivery of therapeutic molecules. Beyond diabetes management, MannKind seeks to explore additional clinical applications for its technology in areas like oncology and endocrinology. Founded in 1991 and headquartered in Westlake Village, California, MannKind has a significant presence in the medical and biotech markets. Its commitment to innovation and patient-centered solutions highlights its role in shaping future therapeutics, contributing to advancements in both diabetes care and potential new frontiers for drug delivery systems.